Alendronate is not indicated for use in children The efficacy and safety were examined in a randomized, double-blind, placebo-controlled two-year study of 139 patients, 4-18 years old, with severe osteogenesis imperfecta Treatment with alendronate did not reduce the risk of fracture There were no statistically significant differences between the alendronate and placebo groups in reduction of bone pain Information on PK parameters, AE profile, and clinical studies
|